Where to Get GLP-3: The GLP-1 Drug Class Explained

Part of the PlexusDx Education Hub: a plain-language primer on the GLP-1 drug class for anyone whose search really means “what is this class and how do I approach it.” Browse all Peptides & GLP-1 education

“Where to get GLP-3” is, at root, a pathway-level question about GLP-1 receptor agonists as a drug class. This article walks through the hormone itself, how receptor agonists work, which medications belong to the class, their FDA-approved uses, the safety profile they share, and the genetics that sit upstream of any GLP-1 decision.

The hormone: what GLP-1 does

Glucagon-like peptide-1 (GLP-1) is an incretin hormone released by enteroendocrine L-cells in the small intestine after eating. It triggers glucose-dependent insulin secretion from pancreatic beta cells, suppresses glucagon from alpha cells, slows gastric emptying, and signals satiety in the hypothalamus. Native GLP-1 lasts only minutes because the enzyme DPP-4 degrades it rapidly in circulation.

How receptor agonists extend that signal

GLP-1 receptor agonists are peptides (and, in emerging cases, small molecules) that bind the GLP-1 receptor while resisting DPP-4 degradation, stretching the half-life from minutes to hours or days. They reproduce native GLP-1’s effects at a pharmacological level: glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, and reduced appetite via central satiety signaling. GIP/GLP-1 dual agonists such as tirzepatide add a second incretin mechanism by also engaging the GIP receptor.

The medications in the class

FDA-approved GLP-1 receptor agonists as of April 2026 include exenatide (Byetta, Bydureon), liraglutide (Victoza, Saxenda), dulaglutide (Trulicity), lixisenatide (historically; discontinued in the U.S.), and semaglutide (Ozempic, Wegovy, Rybelsus). The GIP/GLP-1 dual agonist is tirzepatide (Mounjaro, Zepbound). Retatrutide, an investigational triple agonist (GLP-1/GIP/glucagon), has Phase 3 data but is not FDA-approved. Emerging oral non-peptide agonists such as orforglipron are in late-stage development.

Approved uses across the class

Indications differ by compound and product: type 2 diabetes (most products), chronic weight management (Wegovy, Saxenda, Zepbound), cardiovascular risk reduction in type 2 diabetes (Ozempic, Trulicity, Victoza, Rybelsus), and obstructive sleep apnea in adults with obesity (Zepbound, December 2024). Some products carry pediatric indications. FDA labeling governs what is prescribed for which indication — discuss specifics with a healthcare provider.

The safety profile they share

Every FDA-approved GLP-1 receptor agonist and GIP/GLP-1 dual agonist carries the class boxed warning for thyroid C-cell tumor risk seen in rodent studies. Contraindications include a personal or family history of medullary thyroid carcinoma and Multiple Endocrine Neoplasia syndrome type 2. The most common side effects are gastrointestinal (nausea, vomiting, diarrhea, constipation), usually most pronounced during dose escalation. Reported serious events include pancreatitis, gallbladder events, and acute kidney injury in the context of dehydration.

The genetics upstream of every GLP-1 decision

Variants in FTO, GLP1R, MC4R, and TCF7L2 shape baseline GLP-1, appetite-regulation, and energy-balance biology. They are pathway-level: they do not predict response to any one compound in the class, but they describe the biological terrain every GLP-1 medication operates on. For the underlying pathway explanation, see the PlexusDx primer What is GLP-1?

PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols — available as Semaglutide Injection, Semaglutide Oral, Tirzepatide Injection, and Tirzepatide Oral. Before starting any GLP-1 protocol, the Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, 150+ genetic insights, including the FTO, MC4R, and TCF7L2 variants that shape your baseline biology. That is the test before you invest approach — understand the pathway, then have an informed conversation with your provider.

Related reading on PlexusDx: GLP-1 Receptor Agonist, GLP-1 Drugs, GLP-1 Hormone, What Is GLP-1?.

Disclaimer: This article is educational. PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols; this article covers the mechanism, evidence, and genetic context that informs any decision to use them. PlexusDx does not sell, prescribe, or recommend any other therapeutic peptide in the GLP-1 category beyond semaglutide and tirzepatide (including dulaglutide, liraglutide, retatrutide, cagrilintide, and related compounds). The Precision Peptide Genetic Test analyzes how your genes influence peptide-related biological pathways — it does not predict response to any specific medication. Consult a qualified healthcare provider before beginning any peptide protocol.

Start with the biology: take the Precision Peptide Genetic Test, or explore the Weight Management Protocols.

Frequently Asked Questions

What is a GLP-1 receptor agonist?

A GLP-1 receptor agonist is a peptide (or emerging small molecule) that engages the GLP-1 receptor and resists rapid degradation. It stimulates glucose-dependent insulin secretion, slows gastric emptying, and signals satiety. FDA-approved agonists include semaglutide, tirzepatide (a GIP/GLP-1 dual agonist), liraglutide, and dulaglutide.

How do GLP-1 agonists differ from GIP/GLP-1 dual agonists?

A GLP-1 receptor agonist engages only the GLP-1 receptor. A GIP/GLP-1 dual agonist such as tirzepatide also engages the GIP receptor, adding a second incretin mechanism. Trial data (SURPASS, SURMOUNT) suggests the dual-receptor mechanism may produce larger mean effects on weight and glycemic control in some populations.

Can a genetic test predict my response in this class?

No. The Precision Peptide Genetic Test does not predict response to any specific compound in the class. It reads pathway-level variants in FTO and MC4R, and TCF7L2 that shape baseline GLP-1 and energy-balance biology — the upstream context that applies across every GLP-1 receptor agonist and dual agonist.

Who should not use a GLP-1 receptor agonist?

Per every FDA label in the class, patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 are contraindicated. Patients with severe gastrointestinal disease, a history of pancreatitis, or certain other conditions require careful clinical review. Discuss your full history with a provider.

This article is part of the PlexusDx Education Hub. Browse all Peptides & GLP-1 education